Alphatec Holdings Inc. (NASDAQ:ATEC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday. The firm currently has a $5.75 price target on the medical technology company’s stock. Zacks Investment Research’s price objective would indicate a potential upside of 9.63% from the company’s current price.

According to Zacks, “Alphatec Holdings, Inc. is a medical technology company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders. The Company’s principal product offering includes a variety of spinal implant products and systems consisted of components, such as spine screws and rods, spinal spacers, plates, and various biologics offerings. Alphatec Holdings, Inc. is headquartered in Carlsbad, California. “

Shares of Alphatec Holdings (NASDAQ:ATEC) traded up 1.81% during trading on Monday, reaching $5.34. The company’s stock had a trading volume of 93,314 shares. The company’s 50 day moving average price is $6.38 and its 200 day moving average price is $4.58. Alphatec Holdings has a 12 month low of $1.80 and a 12 month high of $9.65.

About Alphatec Holdings

Alphatec Holdings, Inc is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures.

5 Day Chart for NASDAQ:ATEC

Receive News & Stock Ratings for Alphatec Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec Holdings Inc. and related stocks with our FREE daily email newsletter.